Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials

References 

1. Schüller J, Cassidy J, Dumont E, et al.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 2000;45:291297
2. Budman DR, Meropol NJ, Reigner B, et al.  Preliminary studies of a novel oral fluoropyrimidine carbamate (capecitabine). J. Clin. Oncol. 1998;16:1795–1802
   • MEDLINE
3. Cassidy J, Dirix L, Bisset D, et al.  A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumours. Clin. Cancer Res. 1998;4:2755–2761
   • MEDLINE
4. Mackean M, Planting A, Twelves C, et al.  Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol. 1998;16:2977–2985
   • MEDLINE
5. Van Cutsem E, Findlay M, Osterwalder B, et al.  Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer (results of a randomized phase II study). J. Clin. Oncol. 2000;18:1337–1345
   • MEDLINE
6. Van Cutsem E, Twelves C, Cassidy J, et al.  Oral capecitabine compared with intravenous 5-fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer (results of a large phase III study). J. Clin. Oncol. 2001;19:4097–4106
   • MEDLINE
7. Hoff PM, Ansari R, Batist G, et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer (results of a randomized phase III study). J. Clin. Oncol. 2001;19:2282–2292
   • MEDLINE
8. Blum JL, Jones SE, Buzdar AU, et al.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 1999;17:485–493
   • MEDLINE
9. Blum JL, Dieras V, LoRusso PM, et al.  Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients. Cancer. 2001;92:1759–1768
   • MEDLINE
   • CrossRef
10. O'Reilly SM, Moiseyenko V, Talbot DC, et al. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc Am Soc Clin Oncol 1998, 17, 163 (abstr).
11. O'Shaughnessy J, Blum J, Moiseyenko V, et al.  Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line chemotherapy for advanced/metastatic breast cancer. Ann. Oncol. 2001;12:1247–1254
    • MEDLINE
    • CrossRef
12. Wilke H. Future treatment options with capecitabine in solid tumours. Eur J Cancer 2002, 38, 21–25 (suppl.).
13. de Gramont A, Bosset J-F, Milan C, et al.  Randomised trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer (a French intergroup study). J. Clin. Oncol. 1997;15:808–815
    • MEDLINE
14. Schmoll HJ, Köhne CH, Lorenz M, et al. Weekly 24h infusion of high-dose (HD) 5-fluorouracil (5-FU_24h) with or without folinic acid (FA) vs. bolus 5-Fu/FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): a randomised phase III study of the EORTC GITCCG and the AIO. Proc Am Soc Clin Oncol 2000, 19, 241 (abstr).
15. Liu G, Franssen E, Fitch M, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 1997;15:110–115
    • MEDLINE
16. Borner M, Schöffski P, de Wit R, et al. A randomised crossover trial comparing oral UFT (uracil/tegafur)+leucovorin (LV) and intravenous fluorouracil (FU) +LV for patient preference and pharmacokinetics in advanced colorectal cancer. Proc Am Soc Clin Oncol 2000, 19, 191 (abstr).